SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020-2022.

Publisher: National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC) Country of Publication: United States NLM ID: 9508155 Publication Model: Print Cited Medium: Internet ISSN: 1080-6059 (Electronic) Linking ISSN: 10806040 NLM ISO Abbreviation: Emerg Infect Dis Subsets: MEDLINE

Original Publication: Atlanta, GA : National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), [1995-

HIV Infections*/complications ; HIV Infections*/epidemiology ; COVID-19*/epidemiology ; COVID-19*/prevention & control; Adult ; Humans ; Chicago/epidemiology ; SARS-CoV-2 ; COVID-19 Vaccines ; Reinfection/epidemiology ; Illinois/epidemiology

Understanding if persons with HIV (PWH) have a higher risk for SARS-CoV-2 reinfection may help tailor future COVID-19 public health guidance. To determine whether HIV infection was associated with increased risk for SARS-CoV-2 reinfection, we followed adult residents of Chicago, Illinois, USA, with SARS-CoV-2 longitudinally from their first reported infection through May 31, 2022. We matched SARS-CoV-2 laboratory data and COVID-19 vaccine administration data to Chicago's Enhanced HIV/AIDS Reporting System. Among 453,587 Chicago residents with SARS-CoV-2, a total of 5% experienced a SARS-CoV-2 reinfection, including 192/2,886 (7%) PWH and 23,642/450,701 (5%) persons without HIV. We observed higher SARS-CoV-2 reinfection incidence rates among PWH (66 [95% CI 57-77] cases/1,000 person-years) than PWOH (50 [95% CI 49-51] cases/1,000 person-years). PWH had a higher adjusted rate of SARS-CoV-2 reinfection (1.46, 95% CI 1.27-1.68) than those without HIV. PWH should follow the recommended COVID-19 vaccine schedule, including booster doses.

Cell Mol Immunol. 2021 Jul;18(7):1832-1834. (PMID: 34099890)
Infect Control Hosp Epidemiol. 2021 Jun;42(6):659-668. (PMID: 33077007)
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):118-124. (PMID: 35085218)
N Engl J Med. 2021 Feb 11;384(6):533-540. (PMID: 33369366)
J Infect. 2021 Aug;83(2):237-279. (PMID: 34052241)
Clin Infect Dis. 2021 Jun 15;72(12):e1021-e1029. (PMID: 33252620)
Emerg Infect Dis. 2022 Aug;28(8):1729-1731. (PMID: 35738346)
Clin Infect Dis. 2021 Nov 16;73(10):1882-1886. (PMID: 33718968)
Nat Commun. 2021 Feb 19;12(1):1162. (PMID: 33608522)
Clin Microbiol Infect. 2021 Dec;27(12):1860.e7-1860.e10. (PMID: 34419576)
MMWR Morb Mortal Wkly Rep. 2022 Jan 07;71(1):19-25. (PMID: 34990440)
N Engl J Med. 2022 Mar 31;386(13):1288-1290. (PMID: 35139269)
MMWR Morb Mortal Wkly Rep. 2022 Apr 15;71(15):549-555. (PMID: 35421077)
J Med Virol. 2021 Jan;93(1):506-512. (PMID: 32644223)
JAMA Netw Open. 2022 Jun 1;5(6):e2215934. (PMID: 35671054)
MMWR Recomm Rep. 2014 Apr 11;63(RR-03):1-10. (PMID: 24717910)
J Clin Microbiol. 2021 Mar 19;59(4):. (PMID: 33361342)
JMIR Public Health Surveill. 2022 May 24;8(5):e35311. (PMID: 35486806)
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1081-1083. (PMID: 34383732)
N Engl J Med. 2022 Mar 31;386(13):1207-1220. (PMID: 35172051)
MMWR Morb Mortal Wkly Rep. 2022 Apr 08;71(14):524-526. (PMID: 35389976)
JAMA Intern Med. 2022 Feb 1;182(2):153-162. (PMID: 34962505)
Lancet. 2021 Apr 17;397(10283):1459-1469. (PMID: 33844963)
Eur J Clin Invest. 2022 Oct;52(10):e13845. (PMID: 35904405)
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709. (PMID: 33400782)
Lancet. 2021 Mar 27;397(10280):1204-1212. (PMID: 33743221)
J Investig Med. 2021 Aug;69(6):1253-1255. (PMID: 34006572)
AIDS Care. 2013;25(4):451-8. (PMID: 22894702)
MMWR Morb Mortal Wkly Rep. 2021 Nov 05;70(44):1539-1544. (PMID: 34735425)
Clin Infect Dis. 2022 Apr 28;74(8):1489-1492. (PMID: 34351392)
Clin Case Rep. 2021 Jan 13;9(3):1397-1401. (PMID: 33768853)
J Public Health Manag Pract. 2014 Sep-Oct;20(5):506-12. (PMID: 24335712)
Prev Chronic Dis. 2021 Jul 01;18:E66. (PMID: 34197283)
Am J Transplant. 2021 Aug;21(8):2916-2918. (PMID: 34101990)
Clin Infect Dis. 2022 Aug 24;75(1):e662-e671. (PMID: 35028662)
Lancet Infect Dis. 2022 Jun;22(6):781-790. (PMID: 35366962)
Clin Infect Dis. 2014 Dec 15;59(12):1787-97. (PMID: 25182245)

Keywords: COVID-19; Chicago; HIV/AIDS; Illinois; PWH; PWOH; SARS-CoV-2; United States; public health surveillance; reinfection; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses

0 (COVID-19 Vaccines)

Date Created: 20231025 Date Completed: 20231026 Latest Revision: 20231112

20240513

PMC10617359

10.3201/eid2911.230577

37877555